RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.
RS-601 (1-10 mg/kg) clearly inhibits the bronchoconstriction induced by intravenous administration of U-46619 and LTD4 in a dose-dependent fashion in guinea pigs. RS-1452 (10 mg/kg) significantly inhibits U-46619-induced bronchoconstriction, respectively. RS-601 significantly inhibits the late-phase response and LPS-induced AHR at a dose of 10 mg/kg, but does not affect biphasic bronchial responses. RS-601 (3 and 10 mg/kg) also clearly inhibits the AHR[1].
[1]. Yamada T, et al. Effects of RS-601, a novel leukotriene D(4)/thromboxane A(2) dual receptor antagonist, on asthmatic responses in guinea pigs. Pharmacology. 2003 Sep;69(1):51-8.